COVID-19: Eisai to jointly develop therapeutic drug: Utilization of Eritoran and E6011
-Concluded a joint research and development agreement and started non-clinical research activities-
Eisai:
COVID-19 aggravation measures:
Many cases of COVID-19 patients have been reported to become severe due to acute respiratory distress syndrome (ARDS) and multiple organ failure.
Elucidation of the mechanism of aggravation:
In the process of this aggravation, the formation and exacerbation of angiopathy and the involvement of cytokine storms * are assumed.
However, at this time, the mechanism of SARS-CoV-2 infection and aggravation has not been fully elucidated.
Evaluation of medicinal properties created by Eisai:
In this joint research, we will construct a non-clinical animal model of SARS-CoV-2 infection.
Created by Eisai, which has already been tested
TLR (Toll-Like Receptor) 4 antagonist Eritoran,
Anti-FKN (fractalkine) antibody drug E6011
Evaluate the efficacy of the drug used.
Biomarker search:
We will also promote biomarker search using clinical samples derived from SARS-CoV-2 infected patients.
Through this joint research, we aim to elucidate the mechanism of COVID-19 aggravation and create drugs to prevent aggravation.
News Release: 2020 | Eisai
https://www.eisai.co.jp/news/2020/news202062.html
Eisai: Joint Development Agreement Aiming for Drug Discovery for COVID-19 Utilizing Eritoran and E6011 Concluded
Eisai Co., Ltd.
announced today that it has entered into a joint research agreement withfour research organizations
- KAN Research Institute,
- Center for Global Health and Medicine,
- Nagasaki University,
- Yokohama City University in Japan
concerning the “Development of Therapeutics to Prevent the Aggravation of the Novel Coronavirus Infectious Disease (COVID-19)” (Grant Number: 20fk0108255),
which is a research project with Eisai as the representative research organization.
This joint research project “Development of Therapeutics for Novel Coronavirus Infectious Disease (COVID-19)”
was adopted for the second public call by the Japan Agency for Medical Research and Development (AMED) as part of its operation for promotion of the research and development of innovative treatments for emerging and re-emerging infectious diseases in fiscal year 2020.
In patients with COVID-19
due to the SARS-CoV-2 infection, severe cases such as acute respiratory distress syndrome (ARDS) and subsequent multiple organ failure have been reported.The involvement of the formation and exacerbation of vasculopathy as well as the cytokine storm* in the process of aggravation are assumed.
However, at this time, the mechanism of aggravation based on the SARS-CoV-2 infection is not fully understood.
In this collaborative research,
a non-clinical animal model of SARS-CoV-2 infection will be constructed.Additionally, TLR (Toll-Like Receptor) 4 antagonist eritoran, discovered by Eisai,
and
an anti-FKN (fractalkine) antibody E6011, discovered by Eisai’s research subsidiary KAN Research Institute,
will be evaluated. In addition, this project will promote biomarker research using clinical samples derived from SARS-CoV-2 infected patients.